Mirum Pharma Reports Executive Changes/Compensatory Arrangements

Ticker: MIRM · Form: 8-K · Filed: Jan 16, 2024 · CIK: 1759425

Complexity: simple

Sentiment: neutral

Topics: executive-change, compensation, corporate-governance

TL;DR

**Mirum Pharma just filed an 8-K about executive changes or pay, keep an eye on leadership.**

AI Summary

Mirum Pharmaceuticals, Inc. filed an 8-K on January 16, 2024, reporting an event that occurred on January 11, 2024. This filing indicates a change in the company's leadership or executive compensation arrangements, specifically under Item 5.02, "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers." While the specific details of the change are not provided in this summary, any significant executive changes or compensation shifts can impact investor confidence and the company's strategic direction, which matters to shareholders.

Why It Matters

Changes in executive leadership or compensation can signal shifts in company strategy or financial health, directly influencing investor perception and stock valuation.

Risk Assessment

Risk Level: medium — Without specific details on the executive changes or compensation, the impact on the company's stability and future performance is uncertain, posing a medium risk.

Analyst Insight

Investors should await further details from Mirum Pharmaceuticals regarding the specific nature of the executive changes or compensatory arrangements to assess potential impacts on company strategy and performance.

Key Players & Entities

FAQ

What is the purpose of this 8-K filing by Mirum Pharmaceuticals, Inc.?

This 8-K filing, dated January 16, 2024, is a 'Current Report' pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, specifically addressing 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' under Item 5.02.

When did the event reported in this 8-K filing occur?

The earliest event reported in this 8-K filing occurred on January 11, 2024, as stated in the 'Date of Report (Date of earliest event reported)' section.

What is the trading symbol and exchange for Mirum Pharmaceuticals, Inc.?

Mirum Pharmaceuticals, Inc. trades under the symbol 'MIRM' on the Nasdaq Global Market, as indicated in the 'Securities registered pursuant to Section 12(b) of the Act' section.

What is the business address of Mirum Pharmaceuticals, Inc.?

The business address of Mirum Pharmaceuticals, Inc. is 950 Tower Lane, Suite 1050, Foster City, California, 94404, with a telephone number of (650) 667-4085.

Is Mirum Pharmaceuticals, Inc. considered an emerging growth company?

The filing includes a checkbox to 'Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933', but the box is not checked, implying it is not currently designated as an emerging growth company.

Filing Stats: 630 words · 3 min read · ~2 pages · Grade level 12.3 · Accepted 2024-01-16 16:15:59

Key Financial Figures

Filing Documents

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 11, 2024, the Board of Directors of Mirum Pharmaceuticals, Inc. (the "Company") promoted Peter Radovich, previously the Company's Chief Operating Officer, to the additional position of President, with Christopher Peetz, who previously served as the Company's President and Chief Executive Officer, continuing to serve as the Company's Chief Executive Officer, each effective as of January 16, 2024. Peter Radovich, 45, has served as the Company's Chief Operating Officer since April 2020. Previously, Mr. Radovich worked in various positions at Global Blood Therapeutics, Inc. from November 2014 through April 2020, including as vice president, program leadership and business strategy, senior vice president, operations and executive vice president, operations. During his tenure at Global Blood Therapeutics, Mr. Radovich was responsible for the company's technical operations, supply chain, program management and leadership, quality assurance and commercial strategy and analytics functions. From 2013 to 2014, Mr. Radovich served as Vice President, Global Product Leader – Kyprolis at Onyx Pharmaceuticals, Inc., which was acquired by Amgen, Inc., where he led the company's global, cross-functional product team responsible for the development and commercialization of Kyprolis. Between 2006 and 2013, he held a variety of roles of increasing responsibility in Onyx's commercial organization supporting Kyprolis and Nexavar and was a key member of the deal team for Onyx's acquisition of Proteolix. From 2004 to 2006, Mr. Radovich was at Chiron Corporation (acquired by Novartis AG) in product marketing supporting Proleukin (interleukin-2) in multiple oncology indications. Mr. Radovich received a B.A. in biology and chemistry from Texas Christian University and an MBA from Washington University in St. Louis.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Mirum Pharmaceuticals, Inc. Date: January 16, 2024 By: /s/ Christopher Peetz Christopher Peetz President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing